Drug discovery company, E-therapeutics plc, which is based at Long Hanborough near Witney, has appointed Ali Mortazavi as Chief Executive Officer. He will also retain his position as Chairman of the Company.
Ali Mortazavi was appointed Executive Chairman in February in a management restructure that saw Ray Barlow stepping down as CEO and Steve Medlicott stepping down as CFO.
The Board currently consists of one Executive Director and two Non-Executive Directors. Professor Trevor Jones CBE, Non-Executive Director of e-therapeutics plc said: “Since his appointment in February, Ali has re-energised the Company and, importantly, played a significant role in restructuring the portfolio; including the establishment of a research programme on RNAi …a key area for important new therapies for a number of major diseases.
“We are delighted that in addition to his role as Chairman he has accepted our invitation to lead the team as Chief Executive Officer.”
Ali Mortazavi, added: “Rarely does an opportunity arise to lead a company in an entirely new and burgeoning sector. I believe that etherapeutics has established a key position among the small vanguard of companies across the globe applying computational biology to drug discovery. Our ambition is to take advantage of our momentum to become a major force at this intersection of technology and life sciences.”
In June the company, raised a further £11.6m gross fundraise was successfully completed in July 2020 to enable the Company’s next stage of growth.